<DOC>
	<DOCNO>NCT02494505</DOCNO>
	<brief_summary>The main objective study mycophenolate could decrease proportion patient relapse IVIG taper period IVIG withdrawal .</brief_summary>
	<brief_title>Interest Mycophenolate CIDP Weaning</brief_title>
	<detailed_description>The secondary objective : - Study mycophenolate could improve proportion withdrew patient . - Study mycophenolate could improve reduction IVIG dose could prolong interval two course IVIG compare baseline interval month 12 month 24 ( = spar treatment criterion ) . - Study mycophenolate could short delay perform IVIG withdrawal . - Study mycophenolate could improve clinical score ( ONLS , R-ODS MRC , INCAT sensory , 10 meter test ) pain score month 12 month 24 . - Study mycophenolate could improve quality life month12 month 24 . - Identify clinical , biological electrophysiological factor associate withdrawal . - To assess pharmacokinetics factor ( Area curve measure exposure mycophenolate ) pharmacogenetic factor ( cytochrome carrier , FcgammaR ) associate withdrawal . - Evaluate tolerance Mycophenolate new indication .</detailed_description>
	<mesh_term>Polyradiculopathy</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Patient old eighteen Written inform consent study participation Definite probable CIDP accord EFNS/PNS criterion atypical CIDP ( need meet clinical EFNS/PNS criterion least 2 criterion among EFNS/PNS supplementary criterion ) Being responder ( = decrease least 1 point ONLS score IVIG ) dependent IVIG ( = increase least 1 point ONLS score IVIG withdrawal taper period ) Having receive least 3 course IVIG Negative pregnancy test woman childbearing age Exclusion criterion : No social security benefit Pregnancy intention become pregnant Nursing mother Recent active VIH hepatitis B C , lyme infection Monoclonal IgM gammapathy anti MAG antibodies CANOMAD syndrome Neutropenia &lt; 1G/L Malignancy 10 year inclusion Patients received Mycophenolate History allergy mycophenolate placebo excipient Patients receive immunosuppressive drug 3 month period inclusion Patients receiving : plasma exchange , magnesium hydroxide , aluminium hydroxide , cholestyramine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>chronic inflammatory demyelinate polyradiculopathy</keyword>
	<keyword>intravenous immunoglobulin ( IVIG )</keyword>
	<keyword>withdrawal</keyword>
	<keyword>quality life</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>cost</keyword>
</DOC>